Skip to main content

Advertisement

Log in

Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

We present the case of a 72-year-old male with chronic phase myeloid leukemia. Elevation of the pulmonary artery pressure due to nilotinib therapy was noted. This effect on pulmonary artery pressure was nilotinib dose dependent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. TASIGNA® (nilotinib) capsules prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ. 2010.

  2. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233–7.

    Article  Google Scholar 

  3. Ribeiro AL, Marcolino MS, Bittencourt HN, Barbosa MM. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res. 2008;32:1809–14.

    Article  PubMed  CAS  Google Scholar 

  4. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib and sorafenib on mitochondria function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106:153–61.

    Article  PubMed  CAS  Google Scholar 

  5. Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Preclinical evaluation of potential nilotinib cardiotoxicity. Leuk Res. 2011;35:631–7.

    Article  PubMed  CAS  Google Scholar 

  6. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009;33(6):861–4.

    Article  PubMed  Google Scholar 

  7. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36:e4–6.

    Article  PubMed  Google Scholar 

  8. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011; 11:30.

    Google Scholar 

  9. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967–8.

    Article  PubMed  CAS  Google Scholar 

  10. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182:1171–7.

    Article  PubMed  CAS  Google Scholar 

  11. Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J. 2008;32:232–5.

    Article  PubMed  CAS  Google Scholar 

  12. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27:1485–94.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dariusz Zakrzewski.

About this article

Cite this article

Zakrzewski, D., Seferynska, I., Warzocha, K. et al. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia. Int J Hematol 96, 132–135 (2012). https://doi.org/10.1007/s12185-012-1103-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1103-0

Keywords

Navigation